sugemalimab
cstone pharmaceuticals
['lymsm', 'sugemalimab', 'pdl']
dr. huang on gemstone-201: multi-center phase 2 study of sugemalimab (pdl1 mab) in 80 pts w/r/r enktl orr 46.2% with 37.2% in cr.
median os not reached, 1-year os 68.6%
main sae are pneumonia, fever, sinus node dysfunction, irae involving thyroid and skin #asco22 #lymsm 
4th yr Hem/Onc & T32 aging research fellow @UCSFCancer | Alum: @UMichMedicine @MayoMN_IMRES @UHMed | Interests: women in medicine, lymphoma, #pallonc #geriheme